Low-molecular-weight heparin use in special populations.
Because many obese patients and patients with underlying renal dysfunction require surgical intervention, it is important to examine the dosage recommendations and monitoring required with low-molecular-weight heparins.
Johnson
Peter N
PN
University of Kentucky Chandler Medical Center, Lexington 40536-0293, USA.
Smith
Kelly M
KM
D000925:Anticoagulants / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D015897:Comorbidity; D003401:Creatine / Q000652:urine; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000453:epidemiology*; D008991:Monitoring, Physiologic; D009765:Obesity / Q000453:epidemiology*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D013923:Thromboembolism / Q000453:epidemiology* / Q000517:prevention & control
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D003401:Creatine